How to pass on wealth, AstraZeneca & Ceres: The Companies and Markets Show
This week, the American FDA announced it’s set to review a new breast cancer drug, Enhertu, developed by AstraZeneca (AZN) and its Japanese partner, Daiichi Sankyo. Julian Hofmann and Dan Jones unpack what this did to Astra’s shares, the wider issues facing pharmaceutical companies, plus an update on GSK’s (GSK)…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Investors' Chronicle →
Should we axe inheritance tax on family homes?
How to Navigate the Great Wealth Transfer
Big companies’ big earnings, the Post Office’s new banking pilot and an Asian investment trust superstar
Investment Clinic: I’m 29 – should I still be taking stock tips from my dad?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.